Navigation Links
Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
Date:2/8/2013

NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference, being held February 11-12, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Monday, February 11th, at 2:30 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in '/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
3. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
4. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
8. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
9. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
11. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
(Date:8/26/2014)... what they believe is the thinnest-possible semiconductor, a ... only three atoms thick. , The University of ... single-layer semiconductor materials can be connected in an ... result could be the basis for next-generation flexible ... and solar technologies. , "Heterojunctions are fundamental elements ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) ... HealthShares(TM) Exchange-Traded Funds, today announced,that effective at the ... Pharmaceuticals Inc. (Nasdaq: REGN ) will replace ... HealthShares(TM) Composite Index. MGI Pharma is being,acquired by ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
Cached Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes 2
(Date:8/27/2014)... Calif. , Aug. 27, 2014  WaferGen Bio-systems, ... its previously announced underwritten public offering of units of ... per unit for gross proceeds of $20 million, prior ... payable by the Company.  The shares and warrants are ... Each unit sold in the offering consists of ...
(Date:8/27/2014)... 2014. Using functional near infrared spectroscopy (fNIRS), Kessler ... between people with multiple sclerosis (MS) and healthy ... which brain activation was studied using fNIRS while ... and cognition using functional near infrared spectroscopy (fNIRS) ... 11 by Brain Imaging and Behavior . ...
(Date:8/27/2014)... fish began exploring land and evolved into tetrapods today,s ... fish used their fishy bodies and fins in a terrestrial ... mysteries. , Researchers at McGill University published in the ... Polypterus , to help show what might have happened ... Polypterus is an African fish that can breathe ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Walking fish reveal how our ancestors evolved onto land 2
... is a mystery. Butterfly or baby, cells organize themselves ... and over, patterns emerge in all living creatures. Spiders ... encased in an elegant spiral shell. , This phenomenon ... the forces that govern it are far from clear. ...
... team who - 10 years ago - created the ... Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in ... of the world's leading scientists will discuss a variety ... field that is being hailed as the next revolution ...
... soil can transform the most commonly used flame retardant compound ... be harmful to humans, according to a new laboratory study ... Society journal, Environmental Science & Technology . The study ... of the journal. , The finding, by a team of ...
Cached Biology News:The shape of life: research sheds light on how cells take shape 2Ten years later, Dolly is still making headlines 2Microbes transform 'safest' PBDEs into more harmful compounds 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... stains proteins in polyacrylamide gel after ... 8 ng of protein) with *CoomassieR-G250. ... processes can be performed in 1.5 ... min), proteins can be seen before ...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
Biology Products: